About Genkyotex
Genkyotex is a company based in Geneve (Switzerland) founded in 2006 was acquired by Calliditas Therapeutics in August 2020.. Genkyotex has raised $51.77 million across 6 funding rounds from investors including Société Générale, Calliditas Therapeutics and Edmond de Rothschild. Genkyotex offers products and services including Setanaxib and NOX Inhibitor Platform.
- Headquarter Geneve, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Calliditas Therapeutics Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$51.77 M (USD)
in 6 rounds
-
Latest Funding Round
$5.61 M (USD), Post-IPO
Aug 21, 2018
-
Investors
Société Générale
& 9 more
-
Employee Count
Employee Count
-
Acquired by
Calliditas Therapeutics
(Aug 13, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genkyotex
Genkyotex offers a comprehensive portfolio of products and services, including Setanaxib and NOX Inhibitor Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
NOX inhibitor for potential disease treatments
Platform for developing NOX-based therapeutics
Funding Insights of Genkyotex
Genkyotex has successfully raised a total of $51.77M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.61 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $5.6M
-
First Round
First Round
(30 Jan 2006)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2018 | Amount | Post-IPO - Genkyotex | Valuation |
investors |
|
| Jan, 2015 | Amount | Post-IPO - Genkyotex | Valuation |
investors |
|
| Jul, 2012 | Amount | Series C - Genkyotex | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genkyotex
Genkyotex has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Société Générale, Calliditas Therapeutics and Edmond de Rothschild. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Founded Year | Domain | Location | |
|
Early-stage venture capital is invested in US and Europe.
|
Founded Year | Domain | Location | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genkyotex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genkyotex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genkyotex Comparisons
Competitors of Genkyotex
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genkyotex
Frequently Asked Questions about Genkyotex
When was Genkyotex founded?
Genkyotex was founded in 2006.
Where is Genkyotex located?
Genkyotex is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Is Genkyotex a funded company?
Genkyotex is a funded company, having raised a total of $51.77M across 6 funding rounds to date. The company's 1st funding round was a Series C of $26M, raised on Jan 30, 2006.
What does Genkyotex do?
Genkyotex was founded in 2006 in Geneva, Switzerland, within the biotechnology sector. Small molecule therapeutics are developed by the company to selectively target the NOX family of enzymes, addressing cardiovascular, metabolic, and neurodegenerative diseases. The lead product, GKT831, functions as a dual inhibitor of NOX4 and NOX1 and is currently in clinical development for scleroderma and non-alcoholic steatohepatitis. Operations focus on advancing these inhibitors through clinical stages.
What products or services does Genkyotex offer?
Genkyotex offers Setanaxib and NOX Inhibitor Platform.
Who are Genkyotex's investors?
Genkyotex has 10 investors. Key investors include Société Générale, Calliditas Therapeutics, Edmond de Rothschild, Vesalius Biocapital Partners, and NeoMed.